Cardiff Oncology, Inc.
Cardiff Oncology, Inc. (Nasdaq: CRDF) is a clinical-stage biotechnology company developing cancer therapies based on PLK1 inhibition. Its lead drug candidate, onvansertib, is an oral, selective PLK1 inhibitor being studied in combination with standard-of-care treatments, particularly for RAS-mutated metastatic… From the company’s description.
Over the twelve months to Jun 30, 2026, Cardiff Oncology, Inc. reported revenue of $0.51M, down 6.8% from a year earlier, and a net loss of $40.05M. Operations used $40.85M in cash. In fiscal 2025, it reported revenue of $0.59M, down 13.2% from fiscal 2024, and a net loss of $45.85M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cardiff Oncology, Inc. does
In the company’s own words
Cardiff Oncology, Inc. (Nasdaq: CRDF) is a clinical-stage biotechnology company developing cancer therapies based on PLK1 inhibition. Its lead drug candidate, onvansertib, is an oral, selective PLK1 inhibitor being studied in combination with standard-of-care treatments, particularly for RAS-mutated metastatic colorectal cancer; investigator-led trials also evaluate it in pancreatic cancer, small cell lung cancer, triple-negative breast cancer and chronic myelomonocytic leukemia. The company uses tumor genomics and biomarker testing to guide patient selection and assess treatment response, and relies on third-party manufacturers and distributors for onvansertib used in clinical and nonclinical programs. Cardiff operates as one business segment. In its colorectal cancer program, a Phase 2 trial evaluates onvansertib with chemotherapy and bevacizumab, while Pfizer Ignite supports clinical activities; Cardiff retains economic ownership and control of the drug candidate. Its laboratory is in San Diego, and its principal operations, assets and decision-making functions are in the United States. Its website is www.cardiffoncology.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1213037
- SIC
- 2836
Financial performance, year by year
Fiscal 2012–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cardiff Oncology, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cardiff Oncology, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cardiff Oncology, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cardiff Oncology, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cardiff Oncology, Inc.'s last four quarterly filings that the numbers alone won't show?”